Empagliflozin Is Associated with Fewer Adverse Renal Outcomes
作者： Allan S. Brett
关键词:
摘要: In a recent placebo-controlled randomized trial that involved 7000 patients with long-standing type 2 diabetes and documented cardiovascular disease,
jwatch.org参考文章(1)
Christoph Wanner, Silvio E. Inzucchi, John M. Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, Bernard Zinman, Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes The New England Journal of Medicine. ,vol. 375, pp. 323- 334 ,(2016) , 10.1056/NEJMOA1515920